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An inexpensive enzyme-linked immunosorbent assay method for human immunodeficiency virus type 1
quantitation, ultrasensitive p24 antigen assay (Up24), was compared with RNA viral load assay (VL). Up24 had
100% sensitivity of detection at a viral load of >30,000, with sensitivity of 46.4% at a viral load of <30,000 (232
specimens from 65 seropositive subjects). The assay was highly reproducible, with excellent correlation
between duplicates and among three laboratories.
Human immunodeficiency virus type 1 (HIV-1) viral load
has become the mainstay for monitoring antiretroviral (ARV)
therapy for HIV infection. However, the routinely used viral
load assays are based on amplification of nucleic acid and as a
result require skilled technicians, dedicated laboratory space,
and complex equipment and are generally expensive (3, 5, 8).
As a result, these tests are not readily available in areas where
resources are limited. An inexpensive and technically less de-
manding approach to quantify HIV-1 would be of great value
for places where nucleic acid testing is impractical or prohib-
ited because of resource limitations.
Two potential methods include an assay that detects virion-
associated reverse transcriptase activity (2) and a “boosted”
p24 antigen assay that uses heat dissociation to allow detection
of HIV-1 p24 antigen with sensitivity and reproducibility re-
ported to be comparable to those of RNA viral load testing (1,
3, 5, 10, 11, 12, 14). The assay has been evaluated for several
applications, including pediatric diagnosis (7, 9, 11) and clinical
monitoring of patients on therapy (6, 13, 14). Most studies to
date have been carried out with HIV-1 subtype B-infected
patients (1, 3, 5, 10, 12, 14), although a few studies suggest that
the assay may also work with non-B subtypes (3, 5, 7, 10).
Although technical challenges in transferring the technique
due to the research nature of the assay have hindered the
routine use of the boosted version of the p24 assay outside one
laboratory, the availability of a simpler version based on com-
mercial components could be a major asset for settings with
limited resources if the assay produced results that correlated
well with nucleic acid testing.
Perkin Elmer Life Sciences (Boston, Mass.) has developed
an integrated kit and protocol using components from the
experimental boosted p24 assay, termed the ultrasensitive p24
antigen assay (Up24). In this study Up24 was compared with
RNA viral load assay (VL) in samples from HIV-1-seronega-
tive and HIV-1-seropositive patients that were either drug
naı̈ve or receiving ARV treatment.
(This study was presented in part at the XIV International
AIDS Conference, July 7 to 12, 2002, Barcelona, Spain [R. A.
Respess, A. Cachafeiro, D. G. Withum, S. A. Fiscus, D. R.
Newman, I. Cabruja, B. M. Branson, O. E. Varnier, T. J.
Dondero, abstr. WeOrB1341, 2002].)
A total of 232 plasma specimens from 65 adult U.S. patients
infected with HIV-1 subtype B (83 from untreated and 149
from ARV-treated patients) with previously determined RNA
viral loads were tested under blinded conditions with Up24.
Plasma samples from an additional 219 HIV-seronegative
adult U.S. subjects were tested in a similar blinded manner.
Up24 was performed in duplicate, and the average of the two
results was used for our comparisons.
To determine interlaboratory concordance, a 19-member
proficiency testing panel was prepared by the Centers for Dis-
ease Control and Prevention and tested in duplicate under
identical conditions by three laboratories experienced with
performing Up24.
Samples were tested as described in the protocol provided
with the p24-specific viral load ELAST amplification system kit
(catalog no. NEP116VL; Perkin Elmer Life Sciences), which is
used in combination with a HIV-1 p24 enzyme-linked immu-
nosorbent assay kit (catalog no. NEK050) for Up24. After the
addition of orthopenylenediamine-HCl substrate the plate was
read kinetically for 30 min by using Quanti-Kin detection sys-
tem software (Rilab, Genoa, Italy) as described previously (4).
The colorimetric reaction was stopped after 30 min, and the
endpoint reading was determined for final calculations with the
Quanti-Kin software.
HIV RNA levels for these specimens had been measured
previously by using either version 2.0 or 3.0 of the Versant
bDNA assay (Bayer Corporation, Berkeley, Calif.) as de-
scribed in the product insert.
Log10 transformation was used for comparing the VL and
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Up24 determinations. Pearson correlation coefficients and linear
regressions were determined by using SAS version 8.2 (SAS In-
stitute, Cary, N.C.). Assay results below the limit of detection
were assigned a value of 0 for ease of comparison. Results were
then segregated and analyzed in viral load increments. Pearson
correlation coefficients and linear regressions were also used to
compare duplicate runs and results from different laboratories.
There was a correlation overall between VL and Up24 for
the combined (n  232, r  0.60 [P  0.0001], R2  0.37),
untreated (n  83, r  0.69 [P  0.0001], R2  0.47), and
ARV-treated (n  149, r  0.48 [P  0.0001], R2  0.23)
HIV-1-seropositive samples (Fig. 1). However, there was no
statistical correlation between VL and Up24 for combined,
untreated, or ARV-treated specimens with viral loads of
5,000 copies/ml (n  127). At viral loads of 5,000 copies/
ml, there was a correlation between VL and Up24 for com-
bined (n  105, r  0.65 [P  0.0001], R2  0.42), untreated (n
 55, r  0.62 [P  0.0001], R2  0.38), and ARV-treated
specimens (n  50, r  0.69 [P  0.0001], R2  0.47).
Both VL and Up24 were negative for all 219 HIV-1-sero-
negative specimens. Of the 37 VL-negative HIV-1-seropositive
specimens, 8 from ARV-treated patients were Up24 positive.
Conversely, 79 VL-positive specimens were Up24 negative.
For specimens with viral loads of 1,000 to 10,000 copies/ml,
Up24 sensitivity of detection was 43.6% (24 of 55) for combined,
56.5% (13 of 23) for untreated, and 34.4% (11 of 32) for ARV-
treated groups. For specimens with viral loads between 10,000
and 20,000 copies/ml, Up24 sensitivity of detection was 38.9% (7
of 18) for combined, 57.1% (4 of 7) for untreated, and 27.3% (3
of 11) for ARV-treated groups. For specimens with viral loads of
20,000 to 30,000 copies/ml, Up24 sensitivity of detection was
72.7% (8 of 11) for combined, 100% (6 of 6) for untreated, and
40.0% (2 of 5) for ARV-treated groups. For specimens with viral
loads of 30,000 copies/ml, Up24 sensitivity of detection was
100% for combined (60 of 60), untreated (34 of 34), and ARV-
treated (26 of 26) groups compared to VL.
In all analyses, each specimen was tested in duplicate. There
was a significant correlation between replicates (r  0.90 [P 
0.0001], R2  0.80). Of the 19 proficiency samples tested for
Up24, 2 were negative in all three laboratories and 17 were
positive (Table 1). For the 17 positives, the correlation was
good among all three laboratories: for laboratory A compared
to B (r  0.87 [P  0.0001], R2  0.76) and C (r  0.89 [P 
0.0001], R2  0.79) and between laboratory B and C (r  0.98
[P  0.0001], R2  0.96).
Antiretroviral therapy has become increasingly available to
larger numbers of HIV-infected patients worldwide through
reduced pricing and other programs such as the UNAIDS
Drug Initiative (16). However, the expense and complexity of
the RNA viral load assay make its use for patient monitoring
FIG. 1. Correlation of Up24 and VL for 65 seropositive adult U.S. patients, either untreated (n  83; x) or ARV treated (n  149; Œ).
VOL. 43, 2005 NOTES 507
difficult to successfully implement in resource-limited settings.
With all reagents required to perform the assay now available
in a commercial kit configuration, with easy-to-follow instruc-
tions and dedicated software, some of the difficulties in running
this boosted version of the p24 assay (e.g., requirement to
prepare in-house relevant buffers, need to titrate the ELAST
for each new lot of streptavidin conjugate, and lack of stan-
dardized software for calculation purposes) appear to have
been addressed. Our study found good concordance among
Up24 results from three laboratories, as have others (C. L.
Jennings et al., Abstr. 43rd Intersci. Conf. Antimicrob. Agents
Chemother., abstr. H-1944, 2003). However, the actual signif-
icance of the absolute differences between the laboratories
remains to be determined. The price per assay ($5 to 10) is
lower than that of nucleic acid testing ($17 to 80 per assay for
reagents). An important feature is its enzyme-linked immu-
nosorbent assay-based format, which allows Up24 to be run
with equipment and staff already present in many laboratories
performing routine serologic assays. In our evaluation, there
was good correlation and detection between Up24 for adult
samples with viral loads of 30,000 copies, whether patients
were drug naı̈ve or ARV treated. Although these results sug-
gest that the assay in its current configuration does not have
the sensitivity required for use in routine monitoring of pa-
tients on ARV therapy, a new sample preparation buffer may
improve the sensitivity of the assay to a more useful range
(C. L. Jennings et al., Abstr. 43rd ICAAC; Fiscus et al., Abstr.
11th Conference on Retroviruses and Opportunistic Infec-
tions, abstr. 957, 2004). However, the current Up24 appears to
have sufficient sensitivity to be useful in qualitative pediatric
diagnosis (15), where viral load on average is very high. Fur-
ther evaluation is necessary to confirm reports that Up24 per-
formance in testing non-B subtypes is similar to that reported
here for subtype B (R. A. Respess et al., Abstr. 10th Confer-
ence on Retroviruses and Opportunistic Infections, abstr.
R-21, 2003). Because VL detects intact viral particles while
Up24 detects both virus-associated and nonvirion p24, a rig-
orous evaluation of Up24 needs to be done before the test can
routinely be used for clinical management.
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TABLE 1. Results of proficiency testing panel between three
laboratories routinely running Up24
CDC
panel
Result (pg/ml) in laboratory
A B C
31 16.3 47.8 14
33 14 36.8 5.6
34 5.6 12.6 2.2
35 322.4 313.8 84.8
36 3.1 8.2 1.5
37 70.7 171.9 51.9
38 2.5 7.4 0.9
39 Negative Negative Negative
310 28.8 106.7 13.4
311 4.9 15.5 1
312 21.3 51.7 9.9
313 3.2 6.9 1.3
314 2.7 6.5 1.5
315 2.6 8 1.6
316 21.9 65.9 18.9
317 48.5 143.1 37.6
318 48.5 185.4 37.3
319 Negative Negative Negative
320 38.3 109.1 29.2
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